Edith Schober1, Birgit Rami. 1. Department of Pediatric and Adolescent Medicine, Medical University Vienna, Vienna, Austria. edith.schober@meduniwien.ac.at
Abstract
OBJECTIVE: The objective of this study was to evaluate whether very young children develop more dermatological complications during insulin pump treatment compared with school children. STUDY DESIGN: Cross-sectional study in 78 consecutive children using insulin pump treatment >4 months. RESULTS: Children in group A [n = 40, 28 males (M) and 12 females (F)] were 2.3 +/- 1.3 yr (+/-SD) and those in group B (n = 38, 13 M and 25 F) were 11.0 +/- 2.9 yr old at the start of continuous subcutaneous insulin infusion (CSII). The mean duration of CSII was similar in both groups (23.6 +/- 16.5 months in group A and 21.8 +/- 16.1 in group B). The most common dermatological complications were scars <3 mm (50% in group A vs. 71% in group B, p < 0.05) and lipohypertrophic areas at the insertion sites (45% in group vs. 47% in group B). Local abscesses and blisters were rare findings in both groups (7.5-12%), none leading to interruption or stop of CSII. CONCLUSIONS: Dermatological side effects during CSII are not more frequent or severe in very young diabetic children compared with diabetic children in school age.
OBJECTIVE: The objective of this study was to evaluate whether very young children develop more dermatological complications during insulin pump treatment compared with school children. STUDY DESIGN: Cross-sectional study in 78 consecutive children using insulin pump treatment >4 months. RESULTS:Children in group A [n = 40, 28 males (M) and 12 females (F)] were 2.3 +/- 1.3 yr (+/-SD) and those in group B (n = 38, 13 M and 25 F) were 11.0 +/- 2.9 yr old at the start of continuous subcutaneous insulin infusion (CSII). The mean duration of CSII was similar in both groups (23.6 +/- 16.5 months in group A and 21.8 +/- 16.1 in group B). The most common dermatological complications were scars <3 mm (50% in group A vs. 71% in group B, p < 0.05) and lipohypertrophic areas at the insertion sites (45% in group vs. 47% in group B). Local abscesses and blisters were rare findings in both groups (7.5-12%), none leading to interruption or stop of CSII. CONCLUSIONS: Dermatological side effects during CSII are not more frequent or severe in very young diabeticchildren compared with diabeticchildren in school age.
Authors: Parul J Patel; Kari Benasi; Gina Ferrari; Mark G Evans; Satya Shanmugham; Darrell M Wilson; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2013-10-03 Impact factor: 6.118
Authors: Andrew W Karlin; Trang T Ly; Laura Pyle; Gregory P Forlenza; Laurel Messer; R Paul Wadwa; Daniel J DeSalvo; Sydney L Payne; Sarah Hanes; Paula Clinton; David M Maahs; Bruce Buckingham Journal: Diabetes Technol Ther Date: 2016-05-26 Impact factor: 6.118